NASDAQ:UPB Upstream Bio (UPB) Stock Price, News & Analysis $6.31 -0.26 (-3.96%) Closing price 07/31/2026 04:00 PM EasternExtended Trading$6.30 0.00 (-0.08%) As of 07/31/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Upstream Bio Stock (NASDAQ:UPB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Upstream Bio alerts:Sign Up Key Stats Today's Range$6.29▼$6.6950-Day Range$5.92▼$8.3752-Week Range$5.85▼$33.68Volume297,714 shsAverage Volume473,148 shsMarket Capitalization$343.39 millionP/E RatioN/ADividend YieldN/APrice Target$33.17Consensus RatingHold Company Overview Upstream Bio, Inc. is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges. The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages. In the immuno-oncology sphere, Upstream Bio is exploring therapeutic vaccine constructs designed to activate tumor-specific T cells, while its infectious disease programs seek to induce protective immunity against viral pathogens. By integrating translational biomarkers and adaptive clinical trial designs, the company strives to accelerate candidate selection and optimize dosing regimens. Upstream Bio operates research facilities in the United States and collaborates with academic and industry partners across several regions to advance its programs globally. The company’s leadership team comprises seasoned executives and scientists with deep expertise in virology, vaccine development and regulatory affairs. Upstream Bio is listed on the Nasdaq Global Market under the symbol UPB and continues to build strategic alliances aimed at expanding its pipeline and commercial capabilities.AI Generated. May Contain Errors. Read More Upstream Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreUPB MarketRank™: Upstream Bio scored higher than 54% of companies evaluated by MarketBeat, and ranked 438th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingUpstream Bio has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialUpstream Bio has a consensus price target of $33.17, representing about 425.6% upside from its current price of $6.31.Amount of Analyst CoverageUpstream Bio has only been the subject of 4 research reports in the past 90 days.Read more about Upstream Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Upstream Bio are expected to decrease in the coming year, from ($2.90) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Upstream Bio is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Upstream Bio is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUpstream Bio has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Upstream Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.96% of the float of Upstream Bio has been sold short.Short Interest Ratio / Days to CoverUpstream Bio has a short interest ratio ("days to cover") of 8.18.Change versus previous monthShort interest in Upstream Bio has recently decreased by 11.87%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUpstream Bio does not currently pay a dividend.Dividend GrowthUpstream Bio does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.90 News SentimentUpstream Bio has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Upstream Bio this week, compared to 3 articles on an average week.Search Interest4 people have searched for UPB on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Upstream Bio insiders have not sold or bought any company stock.Percentage Held by Insiders16.46% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsUpstream Bio has minimal institutional ownership at this time.Read more about Upstream Bio's insider trading history. Receive UPB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. UPB Stock News HeadlinesIs Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?June 25, 2026 | insidermonkey.com10 small-cap U.S. healthcare stocks with the weakest momentum gradesJune 24, 2026 | seekingalpha.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.August 2 at 1:00 AM | Banyan Hill Publishing (Ad)Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?June 23, 2026 | insidermonkey.comUpstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First PatientsJune 19, 2026 | businesswire.comUpstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the ...June 14, 2026 | markets.businessinsider.comUpstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key SymptomsJune 14, 2026 | quiverquant.comQUpstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026June 14, 2026 | globenewswire.comSee More Headlines UPB Stock Analysis - Frequently Asked Questions How have UPB shares performed this year? Upstream Bio's stock was trading at $27.15 on January 1st, 2026. Since then, UPB shares have decreased by 76.8% and is now trading at $6.31. How were Upstream Bio's earnings last quarter? Upstream Bio, Inc. (NASDAQ:UPB) issued its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.73) by $0.02. The firm had revenue of $1.03 million for the quarter, compared to analyst estimates of $1.03 million. Upstream Bio had a negative net margin of 4,718.96% and a negative trailing twelve-month return on equity of 43.82%. When did Upstream Bio IPO? Upstream Bio (UPB) raised $200 million in an initial public offering on Friday, October 11th 2024. The company issued 12,500,000 shares at $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair served as the underwriters for the IPO. How do I buy shares of Upstream Bio? Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/13/2026Today8/02/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 UPB's financial health is in the Red zone, according to TradeSmith. UPB has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:UPB Previous SymbolNASDAQ:UPB CIK2022626 Webupstreambio.com Phone(781) 208-2466FaxN/AEmployees38Year Founded2021Price Target and Rating Average Price Target for Upstream Bio$33.17 High Price Target$50.00 Low Price Target$8.00 Potential Upside/Downside+425.6%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($2.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$143.44 million Net Margins-4,718.96% Pretax Margin-4,718.96% Return on Equity-43.82% Return on Assets-42.27% Debt Debt-to-Equity RatioN/A Current Ratio23.14 Quick Ratio23.14 Sales & Book Value Annual Sales$2.85 million Price / Sales120.49 Cash FlowN/A Price / Cash FlowN/A Book Value$6.29 per share Price / Book1.00Miscellaneous Outstanding Shares54,420,000Free Float45,462,000Market Cap$343.39 million OptionableN/A Beta1.26 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:UPB) was last updated on 8/2/2026 by MarketBeat.com Staff. From Our PartnersPass by August 7… or wait until 2027?Right now, your phone is recording exactly where you are. It does this roughly every two minutes. Precise coor...Crypto 101 Media | SponsoredThis AI fund sends investors payouts every ThursdayCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredAI is not overTesla and Alphabet just tumbled, and many investors concluded AI is over. It isn't - the easy AI trade may be....The Oxford Club | SponsoredThe dollar just brokeBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
